Gennova Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 65.00 Cr
- Paid Up Capital ₹ 5.51 Cr
- Company Age 23 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 212.90 Cr
- Satisfied Charges ₹ 133.73 Cr
- Revenue Growth 9.75%
- Profit Growth 83.26%
- Ebitda 42.20%
- Net Worth 16.50%
- Total Assets 14.08%
About Gennova Biopharmaceuticals
Gennova Biopharmaceuticals Limited (GBL) is a leading Public Limited Indian Non-Government Company incorporated in India on 19 June 2001 and has a history of 23 years and eight months. Its registered office is in Pune, Maharashtra, India.
The Corporate was formerly known as Emcure Dragon Biotech Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 65.00 Cr and a paid-up capital of Rs 5.51 Cr.
The company currently has active open charges totaling ₹212.90 Cr. The company has closed loans amounting to ₹133.73 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Gennova Biopharmaceuticals Limited India are Rutuja Gohad as COMPANY SECRETARY and Sanjay Singh as Ceo. Sunil Mehta, Shailesh Ayyangar, Kavita Singh, and Three other members serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231PN2001PLC016253
- Company No.
016253
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2001
- Date of AGM
10 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Gennova Biopharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rutuja Gohad  | Company Secretary | 16-May-2015 | Current |
| Sanjay Singh | CEO | 27-Oct-2020 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sanjay Singh | Whole-Time Director | 19-Apr-2007 | Current |
Shailesh Ayyangar  | Director | 26-Jul-2021 | Current |
| Sunil Mehta | Director | 19-Jun-2001 | Current |
| Kavita Singh | Director | 24-Jan-2023 | Current |
| Samit Mehta | Whole-Time Director | 09-Sep-2011 | Current |
| Satish Mehta | Director | 19-Jun-2001 | Current |
Financial Performance of Gennova Biopharmaceuticals.
Gennova Biopharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.75% increase. The company also saw a substantial improvement in profitability, with a 83.26% increase in profit. The company's net worth Soared by an impressive increase of 16.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gennova Biopharmaceuticals?
In 2023, Gennova Biopharmaceuticals had a promoter holding of 87.95% and a public holding of 12.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Noveltech Feeds Private LimitedShailesh Ayyangar is a mutual person
Emcure Pharmaceuticals LimitedSunil Mehta, Shailesh Ayyangar and 2 more are mutual person
Zuventus Healthcare LimitedShailesh Ayyangar and Satish Mehta are mutual person
Universal Nutriscience Private LimitedShailesh Ayyangar is a mutual person
Uth Beverage Factory Private LimitedSamit Mehta is a mutual person
Shaily Engineering Plastics LimitedShailesh Ayyangar is a mutual person
Charges (Loans)
₹212.90 Cr
₹133.73 Cr
Charges Breakdown by Lending Institutions
- Others : 107.00 Cr
- Axis Bank Limited : 55.90 Cr
- Citi Bank N.A. : 50.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Oct 2022 | Citi Bank N.A. | ₹50.00 Cr | Open |
| 20 May 2022 | Axis Bank Limited | ₹55.00 Cr | Open |
| 02 Sep 2021 | Others | ₹107.00 Cr | Open |
| 30 Jun 2021 | Axis Bank Limited | ₹9.00 M | Open |
| 25 Jun 2021 | Others | ₹22.50 Cr | Satisfied |
How Many Employees Work at Gennova Biopharmaceuticals?
Gennova Biopharmaceuticals has a workforce of 705 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gennova Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gennova Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
